Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Genedrive advances after signing distribution deal with Sysmex Europe

genedrive and Sysmex Europe believe there is a major opportunity to support tackling the global burden of the hepatitis C disease
Hepatitis C virus
This agreement follows the recent CE-IVD Certification from the EU for Genedrive HCV ID Kit

Medtech firm genedrive PLC (LON:GDR) has signed a distribution agreement with Sysmex Corporation, a world leader in clinical laboratory systematisation and solutions.

The agreement is for the Genedrive hepatitis C virus (HCV) ID Kit and Genedrive platform in the Europe, Middle East and Africa (EMEA) region with an initial focus on Africa.

Genedrive is the Aim-listed company's flagship molecular diagnostic system.

Genedrive and Sysmex Europe expect to start targeting end users in decentralised laboratories in multiple countries in Africa in the next few months, with the rest of the EMEA region to follow. 

The UK company will retain responsibility for product development, quality management and manufacturing while Sysmex subsidiary Sysmex Europe will be responsible for sales, marketing, customer support and distribution activities across the EMEA region.

The companies will focus on securing the required regulatory approvals in individual territories of Africa, and genedrive forecasts that sales interest will start to kick in during the 2017/18 financial year.

"We are very pleased to have Sysmex as our first commercial partner for our HCV test, and our agreement represents an important step to provide access to Genedrive across target countries in the African regions," said David Budd, chief executive officer of genedrive PLC.

Matthias Voelkel, Senior Executive Officer of Sysmex Europe GmbH, said: "We expect that providing healthcare professionals with a quick diagnostic result in a decentralised setting will allow them to further improve the management of Hepatitis C infections."

Shares in genedrive opened 2.9% higher at 35.5p.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

July 02 2018
The research and diagnostic company develops cancer-detecting blood tests
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use